Publicaciones en colaboración con investigadores/as de Hospital Universitario de Canarias (3)

2022

  1. In vivo CRISPR-Cas9 inhibition of hepatic LDH as treatment of primary hyperoxaluria

    Molecular Therapy - Methods and Clinical Development, Vol. 25, pp. 137-146

2019

  1. Generation of an induced pluripotent stem cell line (CIMAi001-A) from a compound heterozygous Primary Hyperoxaluria Type I (PH1) patient carrying p.G170R and p.R122* mutations in the AGXT gene.

    Stem Cell Research, Vol. 41

2018

  1. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

    Nature Communications, Vol. 9, Núm. 1